Her2 (ERBB2) Mouse Monoclonal Antibody [Clone ID: HER2-Ab-2]

CAT#: TA355104

Mouse monoclonal Anti-HER2 Antibody



Need it in bulk or conjugated?
Get a free quote

CNY 4,862.00


货期*
7周

规格
    • 100 ug

Product images

经常一起买 (4)
Transient overexpression lysate of v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (ERBB2), transcript variant 1
    • 100 ug

CNY 4,840.00


beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00


Recombinant protein of human v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (ERBB2), transcript variant 1, 20 µg
    • 20 ug

CNY 2,900.00


Recombinant protein of human v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (ERBB2), transcript variant 1, 100 µg
    • 100 ug

CNY 9,998.00

Specifications

Product Data
Clone Name HER2-Ab-2
Recommend Dilution Flow Cytometry, Enzyme-Linked Immunosorbent Assay 1 µg/ml, Western Blot, Immunofluorescence 1~2 µg/ml
Reactivity Human
Host Mouse
Clonality Monoclonal
Immunogen Purified HER2
Formulation PBS (pH 7.4)
Concentration lot specific
Purification IgG purified
Conjugation Unconjugated
Storage Condition Store at -20°C as received.
Predicted Protein Size 137.7 kDa
Gene Name erb-b2 receptor tyrosine kinase 2
Synonyms C-erbB-2; CD340; erbB-2; HER-2; HER-2/neu; HER2; herstatin; NEU; NGL; p185erbB2; TKR1
Reference Data
Protein Families Druggable Genome, Protein Kinase, Transmembrane
Protein Pathways Adherens junction, Bladder cancer, Calcium signaling pathway, Endometrial cancer, ErbB signaling pathway, Focal adhesion, Non-small cell lung cancer, Pancreatic cancer, Pathways in cancer, Prostate cancer
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...